ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Please provide your email address to receive an email when new articles are posted on . Patients with IBD who received rapid infusions of infliximab were not at elevated risk for infusion reaction ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

July 11, 2002 -- The U.S. Food and Drug Administration (FDA) has granted marketing approval to infliximab (Remicade) to provide long-term remission-level control of moderate to severe Crohn's disease.

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

In a double-blind multicenter study by Targan et al., [50] 108 patients with active, refractory, moderate to severe CD (a mean CDAI score at baseline of approximately 300 despite treatment with ...

All eligible patients received an intravenous infusion of infliximab (Remicade, Centocor) at a dose of 5 mg per kilogram of body weight at weeks 0, 2, and 6. A response 12 was defined as a reduction ...

Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Sustained treatment with the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's disease reports a multi-center research team in the 4 May 2002, issue of ...

Infliximab is used to treat a variety of inflammatory disorders; however, infusion reactions can occur that might necessitate discontinuation of treatment. A study in Sweden has evaluated the ...

To evaluate the effect of infliximab over the initial 4 years of treatment on inflammatory ocular attacks and background retinal/disc vascular leakage in patients with refractory uveoretinitis ...

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohn’s disease, conclude authors of a study in this week’s issue of THE LANCET. Crohn’s disease is a ...